Q-omics provides the consensus-scored RAB27A profile across patient tissues and cancer cell-line models. RAB27A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RAB27A is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, RAB27A protein abundance shows 27,865 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, THCA, and GBM as cancer lineages where RAB27A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB27A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB27A survival associations across molecular data types. RAB27A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB27A RNA expression–survival associations across cancer types. High RAB27A expression shows unfavorable associations in KIRP, KICH, MESO, LGG and UVM, but favorable associations in BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RAB27A RNA expression.
This table summarizes RAB27A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RAB27A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB27A shows lower tumor expression in COAD, LUSC, BLCA, KICH and READ and higher tumor expression in THCA. The THCA box plot shows higher RAB27A RNA expression in tumor versus normal tissue (log2 FC = +1.647, t-test p < 0.001).
This table shows molecular features associated with RAB27A in patient tissues and cancer cell lines. In patient samples, RAB27A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB27A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
